http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20070035059-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J63-00 |
| filingDate | 2005-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20070035059-A |
| titleOfInvention | Novel 2-substituted D-homo-estra-1,3,5 (10) -triene as an inhibitor of 17β-hydroxysteroid dehydrogenase type 1 |
| abstract | The present invention relates to a novel 2-substituted D-homo-estra-1,3,5 (10) -triene of formula (I), wherein R 2 is a C 1 -C 8 -alkyl group, C 1 Represents a -C 8 -alkyloxy group or a halogen atom, R 13 represents a hydrogen atom or a methyl group, and R 17 represents a hydrogen atom or a fluorine atom. The present invention also provides pharmaceutically acceptable salts of the compounds, methods for their preparation, and pharmaceutical agents for the prevention and treatment of estrogen-dependent diseases that may be affected by inhibition of 17β-hydroxysteroid dehydrogenase type 1. To its use.n n n Estrogen-dependent disease, 17β-hydroxysteroid dehydrogenase, breast cancer, prostate cancer, endometriosis, 2-substituted D-homo-estratriene |
| priorityDate | 2004-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466242023 |
Total number of triples: 16.